A Clinical Trial Program Enrolling Patients with Dialysis-Dependent and Non-Dialysis-Dependent CKD
Vadadustat has been studied in 17 Phase 1 and Phase 2 studies. Data from these studies supported continued clinical development.
Vadadustat Phase 3 Program for the Treatment of Anemia Due to CKD
Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Cardiovascular Outcomes Studies
Vadadustat is currently being evaluated in four Phase 3 pivotal studies in patients with anemia due to chronic kidney disease (CKD). Each of the 4 studies features a randomized, open-label, active control (darbepoetin alfa), non-inferiority design.
Learn more about our ongoing clinical programs: www.clinicaltrials.gov
If you would like to learn more about our clinical trials, including becoming a participating investigator or referring physician, please email firstname.lastname@example.org.
Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.